Ryan shares groundbreaking advancements in neurodegenerative disease treatment, highlighting the potential of technology like the PONDS device. By measuring brain activity, they aim to revolutionize Alzheimer's drug trials and enhance cognitive function assessment for a brighter future in healthcare.
